
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen's management anticipates over 20% growth in research and development spending by 2025, indicating a commitment to innovation and advancing its therapeutic pipeline. Notably, Uplizna sales surged approximately 58% from the previous quarter and 40% year-over-year, reflecting robust demand and market performance. Additionally, the combination of strong sales growth and pipeline advancements supports the potential for multiple expansion, with an estimated enterprise value (EV) to projected 2026 EBITDA ratio of around 13 times.
Bears say
Amgen's financial outlook appears concerning due to declining sales from key products, particularly as many of its blockbuster drugs face increasing competition and potential biosimilar threats. Additionally, the company's substantial research and development expenditures may strain profitability if newer therapies fail to meet market expectations. Finally, recent acquisitions, while bolstering the product portfolio, have also resulted in increased debt levels, which could impact financial flexibility moving forward.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares